Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs)

Current Treatment Options in Oncology

Volumn 10, Issue 1-2, 2009, Pages 1-15

  Wiernik, Peter H ^a,b  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTINEOPLASTIC AGENT; BORTEZOMIB; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; ERYTHROPOIETIN; FLUDARABINE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; OSTEONECTIN; PLACEBO; POMALIDOMIDE; PREDNISONE; RITUXIMAB; SUNITINIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE;

5Q- SYNDROME; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; AMYLOIDOSIS; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACKACHE; BONE MARROW SUPPRESSION; BONE PAIN; BRADYCARDIA; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYDRATION; HYPOTHYROIDISM; IMMUNOBLASTIC LYMPHOMA; LARGE CELL LYMPHOMA; LASSITUDE; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHADENOPATHY; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; T CELL LYMPHOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; UREMIA; VENOUS THROMBOEMBOLISM; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; SALVAGE THERAPY; THALIDOMIDE; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 70149117963     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0077-x     Document Type: Review

References (102)

1. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC: Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma 49:1238-1245, 2008. doi: 10.1080/10428190802005191
2. Aragon-Ching JB, Li H, Gardner ER, Figg WD: Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Discov 2:167-174, 2007.
3. ParavarMT, Lee DJ: Thalidomide: mechanisms of action. Int Rev Immunol 27:111-135, 2008. doi: 10.1080/08830180801911339
4. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999. doi: 10.1056/NEJM199911183412102
5. Zhu D, Corral LG, Fleming YW, et al.: Immunomodulatory drugs Revlamid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother, 2008, 57: 1849-1851
6. Lu L, Payvandi F, Wu L, et al.: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res, in press, 2008
7. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB: Lenalidomide enhances natural killer cells and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650-4657, 2008. doi: 10.1158/1078-0432.CCR-07-4405
8. Liu Q, Farley KL, Johnson KA, et al.: Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit, in press, 2008
9. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Clin Pharmacol 47:1466-1475, 2007. doi: 10.1177/0091270007309563
10. Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK: Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14:270-280, 2008. doi: 10.1158/1078-0432.CCR-07-1562
11. Moutouh-de Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG, Morris CL, Muller G, Brady H, Chan K: Pomalidomide and lenalidomide regulate eryhtropoiesis and fetal hemoglobin production in human CD34 + cells. J Clin Invest 118:248-258, 2008. doi: 10.1172/JCI32322
12. Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dörken B, Zenke M, Lentzsch S: Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing eryhtropoiesis and promoting myelopoiesis. Blood 105:3833-3840, 2005. doi: 10.1182/ blood-2004-03-0828
13. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006. doi: 10.1056/ NEJMoa061292
14. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA: Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 87:345-352, 2008. doi: 10.1007/s00277-008-0449-0
15. Kelaidi C, Eclache V, Fenaux P: The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 140:267-278, 2008. doi: 10.1111/j.1365-2141.2007.06910.x
16. Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Helström-Lindberg E: Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 104:11406-11411, 2007. doi: 10.1073/pnas.0610477104
17. Ebert BL, Galili N. Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A: An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 5:e35, 2008. doi: 10.1371/journal.pmed.0050035
18. Van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B: First thalidomide clinical trial An multiple myeloma: a decade. Blood 112:1035-1038, 2008. doi: 10.1182/blood-2008-02-140954
19. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006. doi: 10.1200/JCO.2005.03.0221
20. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Bladé J: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171-2177, 2008. doi: 10.1200/JCO.2007.14.1853
21. Von Lillienfeld-Toal M, Hahn-Ast C, Furkert K, et al.: A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol, 2008, 81:247-252
22. Barlogie B, Van Rhee F, Shaughnessy JD Jr, et al.: Seven year median time to progression with thalidomide for smouldering myeloma: Partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood, 2008, 112:3122-3125
23. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-loiseau H: Melphalan and prednisone plus thalidomide versus melphaln and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomized trial. Lancet 370:1209-1218, 2007. doi: 10.1016/ S0140-6736(07)61537-2
24. Palumbo A, Bringhen S, Liberati AM, et al.: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood, 2008, 112:3107-3114
25. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhhal A, Romdhane NB, Omri HE, Elloumi M, Belaaj H, Jeddi R, Aissaou L, Ksouri H, Hassen AB, Msadek F, Saad A, Hsari M, Boukef K, Amouri A, Louzir H, Dellagi K, Abdeladhim AB: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 111:1805-1810, 2008. doi: 10.1182/ blood-2007-07-101212
26. Barlogie B, Pineda-Roman M, van Rhee F, et al.: Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood, 2008, 112:3115-3121
27. Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL: Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma 8:153-158, 2008. doi: 10.3816/CLM.2008.n.018
28. Breitkreutz I, Anderson KC: Thalidomide in multiple myeloma-clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4:973-985
29. Palumbo A, Facon T, Sonneveld P, Bladé J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:3968-3977, 2008. doi: 10.1182/blood-2007-10-117457
30. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K: A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34:442-452, 2008. doi: 10.1016/j.ctrv.2008.02.003
31. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A: The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141:814-819, 2008. doi: 10.1111/j.1365-2141.2008.07147.x
32. Terpos E, Kastritis E, Roussou M, et al.: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, in press, 2008
33. Treon SP, Soumerai JD, Branagan AR, et al.: Thalidomide and rituximab in Waldenstrom's macroglobulinemia. Blood, in press, 2008
34. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW: Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 + progenitor cells. Cancer Res 67:746-755, 2007. doi: 10.1158/ 0008-5472.CAN-06-2317
35. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107:3098-3105, 2006. doi: 10.1182/ blood-2005-08-3450
36. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA: Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141: 41-51, 2008. doi: 10.1111/j.1365-2141.2008.07013.x
37. Schey SA, Fields P, Bartlett JB, Clarke IA, Aahan G, Knight RD, Streetly M, Dalgleish AG: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22:3269-3276, 2004. doi: 10.1200/JCO.2004.10.052
38. Breitkreutz I, Raab MS, Vallet S, et al.: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia, 2008, 22:1925-1932
39. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Fo R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132, 2007. doi: 10.1056/NEJMoa070594
40. Weber D, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesyckyj M, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007. doi: 10.1056/NEJMoa070596
41. Wang M, Dimopoulos MA, Chen C, et al.: Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, in press, 2008
42. Rajkumar SV, Hayman SR, Lacy MO, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005. doi: 10.1182/blood-2005-07-2817
43. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M: BiRD (Biaxin [clarithromycin]/ Revlamid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naïve symptomatic multiple myeloma. Blood 111:1101-1109, 2008 doi: 10.1182/ blood-2007-05-090258
44. Spahn JD, Fost DA, Covar R Martin RJ, Brown EE, Szefler SJ, Leung DY: Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: Results of a pilot study. Ann Allergy Asthma Immunol 87:501-505, 2001.
45. Ohara T, Monishita T, SuzukiH, Massaoka T, Ishi H, Hibi T: Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 24:3723-3730, 2004.
46. Paripati H, Stewart AK, Cabou S, et al.: Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282-1284. doi: 10.1038/sj.leu.2405100
47. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S: Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated myeloma patients. Leukemia 22:1280-1281, 2008. doi: 10.1038/sj.leu.2405035
48. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R: Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 14:795-798, 2008. doi: 10.1016/j.bbmt.2008.04.008
49. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A: Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 8:865-874, 2008. doi: 10.1586/ 14737140.8.6.865
50. Armoiry X, Aulagner G, Facon T: Lenalidomide in the treatment of multiple myeloma: A review. J Clin Pharm Ther 33:219-226, 2008. doi: 10.1111/j.1365-2710.2008.00920.x
51. Dimopoulos MA, Kastritis E, Rajkumar SV: Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22:1343-1353, 2008. doi: 10.1038/ leu.2008.123
52. Hideshima T, Raje N, Richardson PG, Anderson KC: A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag 4:129-136, 2008.
53. Caers J, Vande Broek I, De Raeve H, et al.: Multiple myeloma, an update on diagnosis and treatment. Eur J Haematol, 2008, 81:329-343
54. Anargyrou K, Dimopoulos MA, Sezer O, Terpos E: Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 49:677-689, 2008. doi: 10.1080/ 10428190701861686
55. Moreau P, Hulin C, Facon T: Frontline treatment of multiple myeloma in elderly patients. Blood Rev, 2008, 22:303-309
56. Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H: LenalAdomide: a new therapy for multiple myeloma. Cancer Treat Rev 34:283-291, 2008. doi: 10.1016/j.ctrv.2007.12.005
57. Palumbo A, Dimopoulos M, Miguel JS, et al.: Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev, in press, 2008
58. Mateos MV, Garcia-Sanz R, Colado E, Olazbal J, San-Miguel J: Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 140:324-326, 2008. doi: 10.1111/ j.1365-2141.2007.06946.x
59. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM: Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 29:1-8, 2008.
60. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008. doi: 10.1182/blood-2007-10-116129
61. Chanan-Khan A, Porter CW, Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol 7:480-488, 2006. doi: 10.1016/ S1470-2045(06)70723-9
62. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczmzn MS: Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106:3348-3352, 2005. doi: 10.1182/blood-2005-02-0669
63. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006. doi: 10.1200/JCO.2005.05.0401
64. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008. doi: 10.1182/blood-2007-12-130120
65. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26:2519-2525, 2008. doi: 10.1200/JCO.2007.13.9709
66. Moutouh-de-Parseval LA, Weiss L, DeLAp RJ, Knight RD, Zeldis JB: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25:5047, 2007. doi: 10.1200/ JCO.2007.14.2141
67. Chanan-Khan AA, Whitworth A, Bangia N, et al.: Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol, 2008, 26:4851-4852
68. Lapalombella R, Yu B, Triantafillou G, et al.: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, in press, 2008
69. Srinivasan S, Schiffer CA: Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Leuk Res, in press, 2008
70. Makower D, Venkatraj U, Dutcher JP, Wiernik PH: Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leuk Lymphoma 23:617-619, 1996. doi: 10.3109/ 10428199609054873
71. Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD: Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: A phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140:313-319, 2008. doi: 10.1111/j.1365-2141.2007.06937.x
72. Gottardi M, Danesin C, Canal F, Paolo Dei Tos A, Maria Stefani P, Calistri E, Salvadori U, Gherlinzoni F: Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Leuk Lymphoma 25:1-3, 2008.
73. Xu W, Celeridad M, Sankar S, Webb DR, Bennett BL: CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol 128:392-399, 2008. doi: 10.1016/j.clim.2008.04.009
74. Wiernik PH, Lossos IS, Tuscano JM, et al.: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol, 2008, 26:4952-4957
75. Coiffier B, Haioun N, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capedeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 92:1927-1932, 1998.
76. Wiernik PH, Vose JM, Moore TD, et al.: Results from a phase II study investigating the efficacy and safety of linalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. Proc Eur Hematol Assn, 2008
77. Witzig TE, Wiernik PH, Moore T, et al.: Phase II multi-center study of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol, submitted, 2008
78. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140:36-45, 2008.
79. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984-5992, 2005. doi: 10.1158/1078-0432.CCR-05-0577
80. Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544-1552, 2008. doi: 10.1200/ JCO.2007.14.5367
81. Friedberg JW: Treatment of follicular non-Todgkin's lymphoma: the old and the new. Semin Hematol 45S2:S2-S6, 2008.
82. Leonard JP, Martin P, Barrientos J, Elstrom: Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 45S2:S11-S16, 2008.
83. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bhrer C, Henze G, Seeger K, Wellmann S: The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12:5526-5532, 2006. doi: 10.1158/ 1078-0432.CCR-06-0719
84. Palladini G, Russo P, Lavatelli F, et al.: Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol, in press, 2008
85. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470, 2007. doi: 10.1182/blood-2006-07-032987
86. Hussein MA: Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95:924-930, 2006.
87. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079-2080, 2006 doi: 10.1056/ NEJMc053530
88. Rajkumar SV, Blood E: Letter to the editor. N Engl J Med 354:2080, 2006.
89. Gieseler F: Pathphysiological considerations in thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost 99:1001-1007, 2008.
90. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A: Thromboembolic events with lenalidomide-base therapy for multiple myeloma. Cancer 112:1522-1528, 2008. doi: 10.1002/cncr.23336
91. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, BladJ, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lillienfeld-Toal M, Lonial S, Morgan GJ, Oriowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423, 2008. doi: 10.1038/sj.leu.2405062
92. Johnson DC, Corthais S, Ramos C, et al.: Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, in press, 2008
93. Zonder JA, Barlogie B, Durie BGM, et al.: Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis. Blood 2006, 108:403. doi: 10.1182/blood-2006-01-0154
94. Niesvizky R, Martinez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M: Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 48:2330-2337, 2007. doi: 10.1080/ 10428190701647887
95. Drouet L: Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathol Biol (Paris) 56:195-204, 2008. doi: 10.1016/j.patbio.2008.02.013
96. Klein U, Kosely F, Hillenga J, et al.: Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol, in press, 2008
97. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P: Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296:2558-2560, 2006. doi: 10.1001/ jama.296.21.2558-c
98. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyll P, Trent D, Francis CW: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007. doi: 10.1200/JCO.2007.14.1283
99. Hirsh J: Riskof thrombosis with lenalidomide and its prevention with aspirin. Chest 131:275-277, 2007. doi: 10.1378/chest.06-2360
100. Menon S, Habermann T, Witzig T: Lenalidomide-associated hypothyroidism. Leuk Lymphoma 48:2465-2467, 2007. doi: 10.1080/10428190701704613
101. Darabi K, Kantammei S, Wiernik PH: Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 24:e59, 2006. doi: 10.1200/ JCO.2006.08.4053
102. McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA: The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int Immunopharmacol 6:1194-1203, 2006. doi: 10.1016/ j.intimp.2006.03.001